Nocion Therapeutics, Inc.

Nocion Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapies called "nocions." These nocions are charged sodium channel blockers that selectively target and silence actively firing nociceptors, the nerves responsible for pain, itch, and cough. Nocion's approach aims to provide targeted, robust, and sustained relief for a wide range of conditions arising from neurogenic inflammation. The company's mission is to safely alleviate the suffering of millions of patients with these conditions.

Nocion's platform is based on a deep understanding of the physiology of nociceptors and their role in various diseases. The company has a strong scientific foundation, originating from collaborations with researchers at Harvard University and Boston Children's Hospital, and has garnered significant investment from leading venture capital firms. Nocion is currently advancing its lead program, Taplucainium, a dry powder for inhalation, towards a Phase 2b clinical trial in chronic cough patients. The company's commitment to developing innovative and effective treatments for conditions like cough, itch, and pain makes it a promising player in the biopharmaceutical industry.

Nocion Therapeutics is a biopharmaceutical company dedicated to revolutionizing the treatment of conditions arising from neurogenic inflammation. They develop "nocions," a novel class of small molecule charged sodium channel blockers, that selectively target and silence actively firing nociceptors, the nerves responsible for pain, itch, cough, and inflammation. By providing targeted, robust, and sustained relief, Nocion aims to safely alleviate the suffering of millions of patients with these debilitating conditions.

Nocion Therapeutics promotes a culture of innovation, collaboration, and patient-centricity. They foster a collaborative environment where talented individuals with diverse backgrounds can come together to develop novel therapies that address unmet medical needs. The company is driven by a commitment to improving the lives of patients and is dedicated to creating a positive impact on the world.